

From: Thomson Reuters <th.info@thomsonreuters.com>
Sent: Tuesday, May 31, 2011 5:03 PM
To: Hanchett, James (DPH)
Subject: Tomorrow the Switch is Made to Micromedex 2.0


[View as a Web page](#)

TOMORROW THE SWITCH IS MADE TO MICROMEDEX 2.0



As of tomorrow, June 1, 2011 Micromedex 1.0 will no longer be available for customers in the U.S. and Canada.

Tomorrow when you log in to Micromedex, you will see Micromedex 2.0



Micromedex is the most reliable, trusted name in evidence-based clinical reference. We lead the industry because of our unmatched editorial process, reliable content, and innovative user-friendly enhancements.

[Learn More about Micromedex 2.0 by watching a brief tutorial video](#)

[Or for more information about Micromedex 2.0, visit our website.](#)

*Access to Micromedex 1.0 will continue for customers outside the U.S. and Canada until a migration date later in 2011, to be announced.



(Did someone forward this email to you? [Subscribe now](#) to receive future communications.)

[Manage your subscriptions here](#)
To ensure that you continue receiving our emails, please add us to your safe sender list.

This email was sent to: James Hanchett
This email was sent by: The Healthcare business of Thomson Reuters
1500 Spring Garden Street, Fourth Floor, Philadelphia, PA 19130 USA
We respect your right to privacy. [View our policy.](#)

Our dedicated training and support teams are standing by to help.

If you have a support question or would like to request training, contact us:

Within the U.S. and Canada:
Call +1 877 843 6796, and say "Micromedex"
Select Option '3'

Online:
www.micromedex.com/request

[Click here to watch a brief tutorial video on Micromedex 2.0](#)

